Article Versions Notes

Macedo LB, Nogueira-Librelotto DR, Mathes D, de Vargas JM, da Rosa RM, Rodrigues OED, Vinardell MP, Mitjans M, Rolim CMB. Overcoming MDR by Associating Doxorubicin and pH-Sensitive PLGA Nanoparticles Containing a Novel Organoselenium Compound—An In Vitro Study. Pharmaceutics. 2022; 14(1):80. https://doi.org/10.3390/pharmaceutics14010080

Macedo, Letícia Bueno, Daniele Rubert Nogueira-Librelotto, Daniela Mathes, Josiele Melo de Vargas, Raquel Mello da Rosa, Oscar Endrigo Dorneles Rodrigues, Maria Pilar Vinardell, Montserrat Mitjans, and Clarice Madalena Bueno Rolim. 2022. "Overcoming MDR by Associating Doxorubicin and pH-Sensitive PLGA Nanoparticles Containing a Novel Organoselenium Compound—An In Vitro Study" Pharmaceutics 14, no. 1: 80. https://doi.org/10.3390/pharmaceutics14010080

Macedo, L. B., Nogueira-Librelotto, D. R., Mathes, D., de Vargas, J. M., da Rosa, R. M., Rodrigues, O. E. D., Vinardell, M. P., Mitjans, M., & Rolim, C. M. B. (2022). Overcoming MDR by Associating Doxorubicin and pH-Sensitive PLGA Nanoparticles Containing a Novel Organoselenium Compound—An In Vitro Study. Pharmaceutics, 14(1), 80. https://doi.org/10.3390/pharmaceutics14010080